首页> 外文期刊>Pathology >Variation in BCL2 protein expression in follicular lymphomas without t(14;18) chromosomal translocations.
【24h】

Variation in BCL2 protein expression in follicular lymphomas without t(14;18) chromosomal translocations.

机译:没有t(14; 18)染色体易位的滤泡性淋巴瘤中BCL2蛋白表达的变化。

获取原文
获取原文并翻译 | 示例
           

摘要

The hallmark of follicular lymphoma is the t(14;18)(q32;q21) chromosomal translocations that lead to deregulation of BCL2 expression in tumour cells. However, not all cases of follicular lymphoma express BCL2, nor is the t(14;18) translocation always present. Follicular lymphomas lacking the BCL2 rearrangement are less well studied with regards to their immunohistochemical and molecular features. This study aims to investigate the BCL2 protein expression pattern in t(14;18) negative follicular lymphomas.BCL2 protein expression pattern was analysed in 26 cases of t(14;18) negative follicular lymphoma [determined by fluorescence in situ hybridisation (FISH)], using antibodies against two-different epitopes, i.e., the widely-used antibody BCL2/124 and an alternative antibody E17.Two of the t(14;18) negative cases showed evidence of BCL2 amplification and trisomy 18. A total of 13 cases (50%) lacked BCL2 expression. In 10 cases (38%) the expression was heterogeneous and in only three cases (12%) the BCL2 expression was strongly positive. These cases could thus be subdivided into three subgroups: Group I, normal BCL2 genes (i.e., no evidence of translocation or amplification), and BCL2 protein negative; Group II, normal BCL2 genes but BCL2 protein positive; and Group III, presence of other genetic alterations, i.e., BCL2 amplification and trisomy 18, and BCL2 protein positive.This study suggests that it may be possible on the basis of staining to predict that the t(14;18) translocation is absent if a case is either negative for BCL2 protein with different antibodies or has heterogeneous BCL2 expression, possibly acquired through a physiological process of differentiation.
机译:滤泡性淋巴瘤的标志是导致肿瘤细胞中BCL2表达失调的t(14; 18)(q32; q21)染色体易位。但是,并非所有的滤泡性淋巴瘤病例都表达BCL2,也不总是存在t(14; 18)易位。缺乏BCL2重排的滤泡性淋巴瘤对其免疫组织化学和分子特征的研究较少。本研究旨在探讨t(14; 18)阴性滤泡性淋巴瘤中BCL2蛋白的表达模式。对26例t(14; 18)阴性滤泡性淋巴瘤中BCL2蛋白的表达模式进行分析[通过荧光原位杂交(FISH)确定],使用针对两种不同表位的抗体,即广泛使用的抗体BCL2 / 124和替代抗体E17。t(14; 18)阴性病例中有2例显示出BCL2扩增和18三体性的证据,总共13例。病例(50%)缺乏BCL2表达。在10例(38%)中,表达是异质的,仅在三例(12%)中,BCL2表达是强阳性的。因此,这些病例可分为三个亚组:第一组,正常的BCL2基因(即,没有移位或扩增的证据),而BCL2蛋白阴性;第二组,正常的BCL2基因,但BCL2蛋白阳性;和第三组,存在其他遗传改变,即BCL2扩增和三体性18,以及BCL2蛋白阳性。这项研究表明,如果有染色的话,可能预测t(14; 18)易位对于带有不同抗体的BCL2蛋白阴性的病例,或具有异质BCL2表达的病例,可能是通过生理分化过程获得的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号